Protagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024. In the quarter to June 2026, revenue grew 3,749.2%, EPS grew 549.1% and free cash flow grew 839.7%, each against the same quarter a year earlier.
Follow PTGX
Protagonist Therapeutics, Inc. (PTGX) EV/Sales
As of 16 October 2026, Protagonist Therapeutics, Inc. (PTGX) trades at a EV/Sales of 27.4×. Over the past ten years it has ranged from −1,712× (November 2019) to 500× (February 2020); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 109× | 2,296.89% |
| FY2024 | 4.5× | (79.35%) |
| FY2023 | 21.9× | 231.27% |
| FY2022 | 6.6× | (85.71%) |
| FY2021 | 46.3× | 233.64% |
| FY2020 | 13.9× | (94.59%) |
| FY2019 | 257× | 36,574.55% |
| FY2018 | 0.7× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 25.9× | (69.63%) |
| Mar 2026 | 85.4× | (21.36%) |
| Dec 2025 | 109× | 518.79% |
| Sep 2025 | 17.5× | 24.41% |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CAI Caris Life Sciences,�Inc. compare | 8.3× |
| TGTX TG Therapeutics, Inc. compare | 9.8× |
| AXSM Axsome Therapeutics, Inc. compare | 10.2× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 10.9× |
| KRYS Krystal Biotech, Inc. compare | 19.3× |
| PTGX Protagonist Therapeutics, Inc. | 27.4× |
| KYMR Kymera Therapeutics, Inc. compare | 91.4× |
| CYTK Cytokinetics, Incorporated compare | 121× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)